Sihuan Pharmaceutical Holdings Group Ltd is pleased to announce that the Group, as sole agent, will introduce the ELASTY facial embedding thread (thread lifting) and private-use thread products of Dongbang Medical Co., Ltd. of Korea (“Dongbang Medical Korea”) to China. Both of the above products have been approved in China and such approval could speed up launch in the market. The ELASTY facial embedding thread and private-use thread products have been approved in China and such approval could speed up launch in the market.
The four facial embedding thread (thread lifting) products in relation to which the Group becomes the sole agent include ELASTY LINE, MESHFILL, FORTE DOUBLE and UNICONE DOUBLE. The above-mentioned products have been certified by U.S. Food and Drug Administration (the “FDA”) and obtained European Union CE certification, and acquired the Class III registration of import medical device from the FDA in 2019. According to the analysis of Frost & Sullivan, the potential market of embedding thread products in China amounted to approximately RMB1 billion in 2019, and its expected potential market will amount to RMB3.2 billion in 2024 with a CAGR of 26%.
The ELASTY LINE brand belongs to the embedding thread brand of Dongbang Medical Korea. ELASTY LINE is made by adopting safe and absorbable thread materials, PPDO thread (the latest generation). In clinical application, they have the following characteristics such as (1) no knotting, which can reduce the risk of inflammation and infection; (2) high product quality standards, which can prevent facial depression; (3) good toughness combined with 3D coldpressing laminating technology, which can resist tension; (4) extended barbed head anchor cone to prevent thread displacement. In relation to the private-use threads for which the Group becomes the sole agent, medical polypropylene materials are adopted, which are safe and convenient to use.
Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group said: " The introduction of ELASTY LINE products and private-use thread products into the Group’s medical aesthetics platform will not only enrich and expand the platform’s product portfolio, but also reflect the Group’s product layout strategy towards diversification and internationalization. The Group expects to expand the market awareness of its products and brands through the implementation of marketing projects and reasonable pricing. The Group will deepen communication with medical institutions and doctor groups to further improve service standards and expand market share. The Group will also develop its ability to compete against its peers so as to outrun its competitors and to become the leading and first-class medical aesthetics platform."